Acorda Therapeutics Inc. | Mutual Funds
Mutual Funds that own Acorda Therapeutics Inc.
iShares Core S&P Small Cap ETF
2,580,082
5.43%
0
0.16%
09/06/2018
Fidelity Select Biotechnology Portfolio
1,828,214
3.85%
0
0.56%
07/31/2018
Vanguard Small Cap Index Fund
1,181,500
2.49%
12,922
0.04%
07/31/2018
Vanguard Total Stock Market Index Fund
1,166,083
2.46%
1,334
0%
07/31/2018
Fidelity Select Health Care Portfolio
970,000
2.04%
0
0.37%
07/31/2018
Government Pension Fund - Global (The)
967,797
2.04%
535,434
0%
12/31/2017
Fidelity Series Small Cap Opportunities Fund
950,471
2%
61,500
0.43%
04/30/2018
iShares Russell 2000 ETF
904,567
1.91%
0
0.05%
09/06/2018
ClearBridge Small Cap Growth Fund
809,213
1.7%
-50,000
0.64%
01/31/2018
SPDR S&P Biotech ETF
805,777
1.7%
2,073
0.4%
09/06/2018
| Address |
420 Saw Mill River Road
Ardsley New York 10502
United States
|
|
Employees
|
- |
| Website |
http://www.acorda.com |
| Updated |
07/08/2019 |
| Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. |
